KeyCorp Raises Integer (NYSE:ITGR) Price Target to $144.00

Integer (NYSE:ITGR) had its price objective hoisted by KeyCorp from $139.00 to $144.00 in a research report sent to investors on Tuesday, Benzinga reports. The firm currently has an overweight rating on the medical equipment provider’s stock.

Several other research firms have also issued reports on ITGR. Citigroup upped their price objective on Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. Truist Financial upped their price objective on Integer from $145.00 to $150.00 and gave the company a “buy” rating in a research note on Monday. Bank of America upped their price objective on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Benchmark restated a “buy” rating and issued a $130.00 price objective on shares of Integer in a research note on Wednesday, October 2nd. Finally, Oppenheimer assumed coverage on Integer in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $138.71.

Integer Stock Performance

ITGR opened at $130.42 on Tuesday. Integer has a 52-week low of $69.40 and a 52-week high of $133.53. The firm has a market capitalization of $4.37 billion, a PE ratio of 45.13, a PEG ratio of 1.86 and a beta of 1.08. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.96 and a current ratio of 3.29. The business’s 50-day simple moving average is $126.52 and its 200 day simple moving average is $120.48.

Integer (NYSE:ITGR) last released its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.06. Integer had a return on equity of 11.48% and a net margin of 6.31%. The business had revenue of $436.20 million for the quarter, compared to analyst estimates of $437.00 million. During the same quarter in the prior year, the company posted $1.14 earnings per share. Integer’s revenue was up 9.0% on a year-over-year basis. As a group, sell-side analysts expect that Integer will post 5.3 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jean M. Hobby sold 11,960 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the sale, the director now owns 2,280 shares of the company’s stock, valued at $272,824.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Integer

A number of large investors have recently added to or reduced their stakes in ITGR. Contravisory Investment Management Inc. grew its position in Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 80 shares in the last quarter. Quest Partners LLC grew its position in Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 332 shares in the last quarter. GAMMA Investing LLC grew its position in Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 142 shares in the last quarter. Headlands Technologies LLC bought a new stake in Integer during the first quarter worth $106,000. Finally, Innealta Capital LLC bought a new stake in Integer during the second quarter worth $110,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.